Hartford,CT-based Aetna announced that its board of directors decided to split the company's global health and global financial services into two independent, publicly traded companies.
Hartford,CT-based Aetna announced that its board of directors decided to split the company's global health and global financial services into two independent, publicly traded companies.
"We strongly believe that the interests of our shareholders, employees, customers and the communities in which we operate are well served by this plan and by the additional steps we will be taking to improve our business," said Aetna chairman and CEO William H. Donaldson.
Aetna's other steps include:
•Â The sale of international assets that do not fit with the strategies of the newly independent health and wealth businesses, or provide an adequate return on capital.
•Â Finalizing plans to capture strategic healthcare Internet opportunities that leverage Aetna's healthcare information technology assets.
•Â A comprehensive review of the company's health business model and strategies with the goal of building on the franchise and improving financial performance in addition to relationships with physicians, hospitals and patients.
•Â Additional, undisclosed efforts to strengthen the financial services business and enhance its products and services.
•Â The acceleration of an existing cost-reduction program and additional reductions resulting from the company's restructuring and strategic review.
According to Donaldson, the plan came in part from a desire to better accommodate the changing managed care environment. "In health, we will examine our business model in view of a rapidly changing environment that increasingly emphasizes choice and empowerment," said Donaldson. "Our goal is to improve relations with physicians and hospitals, do a better job of meeting the expectations of customers and patients and enhance our financial performance."
Decisions have yet to be made on company names, headquarter locations, corporate staffs and boards of directors for the two companies. The move is also subject to obtaining regulatory approvals and satisfaction of certain legal requirements. PR
What Every Pharma CEO Should Know About Unlocking the Potential of Scientific Data
December 11th 2024When integrated into pharmaceutical enterprises, scientific data has the potential to drive organizational growth and innovation. Mikael Hagstroem, CEO at leading laboratory informatics provider LabVantage Solutions, discusses how technology partners add significant value to pharmaceutical R&D, in addition to manufacturing quality.
Key Findings of the NIAGARA and HIMALAYA Trials
November 8th 2024In this episode of the Pharmaceutical Executive podcast, Shubh Goel, head of immuno-oncology, gastrointestinal tumors, US oncology business unit, AstraZeneca, discusses the findings of the NIAGARA trial in bladder cancer and the significance of the five-year overall survival data from the HIMALAYA trial, particularly the long-term efficacy of the STRIDE regimen for unresectable liver cancer.